- FUJIFILM Diosynth Biotechnologies and Regeneron (REGN, Financial) have signed a 10-year, $3 billion manufacturing agreement.
- The Holly Springs, North Carolina facility will commence operations in 2025, expanding through 2026 and beyond.
- FUJIFILM aims to create 1,400 new jobs in North Carolina by 2031, enhancing its biopharmaceutical manufacturing capabilities.
FUJIFILM Diosynth Biotechnologies and Regeneron Pharmaceuticals, Inc. (REGN) have entered into a 10-year manufacturing supply agreement valued at over $3 billion. This strategic partnership ensures the U.S.-based production of Regeneron's biologic medicines and will operate through FUJIFILM's new large-scale facility in Holly Springs, North Carolina. This facility is anticipated to commence operations in 2025, with plans for additional capacity rolling out in 2025, 2026, and the following years.
The Holly Springs site is part of FUJIFILM's kojoXâ„¢ interconnected manufacturing network, which is designed to enhance supply chain security with standardized equipment and processes globally. This facility is a component of FUJIFILM's $7 billion expansion projects in the U.S. and Europe.
In line with these expansions, FUJIFILM has invested approximately $4 billion in U.S. biopharmaceutical manufacturing capacities and has already created 500 new positions, moving towards the goal of 1,400 new jobs in North Carolina by 2031. This agreement represents a mutual commitment, with Regeneron securing critical manufacturing capacity and FUJIFILM demonstrating its technical expertise and readiness to meet industry demands.
For Regeneron, this partnership not only provides a stable revenue stream but also strengthens its ability to deliver biologic medicines reliably without substantial capital investments in manufacturing infrastructure. This long-term commitment, estimated at over $300 million annually, underscores the importance of supply chain security in Regeneron's strategy.
